Investigational Gout Drugs Do Well in Clinical Trials
Two major American drug companies are racing to get rival new gout medications to market. Both gout medicines take novel approaches to treating refractory gout - gout that hasn't already responded well to current treatment.
Ardea Biosciences had been the first one to announce prosperous clinical trials of its experimental gout drug RDEA594, also known as Lesinurad. Lesinurad's mechanism of action is different from that of the commonly prescribed xanthine oxidase inhibitors gout medications (such as allopurinol and febuxostat), which decrease the development of uric acid.
Lesinurad is often a URAT1 transporter inhibitor which usually increases elimination of uric acid with the kidneys. Lesinurad is also active against another important regulator of urate secretion, OAT4. OAT4 is thought to be responsible for the high uric acid levels in gouty arthritis patients whose condition is caused or worsened by diuretics.
The Lesinurad study involved 208 gout patients who had high blood urate levels for at least A few months, even while taking the gout drug allopurinol. Sufferers continued on allopurinol and were randomly assigned to receive either a placebo or lesinurad at doses of 200 mg, 400 mg, or 600 mg for four weeks.
Preventing Gout Attacks with Diet
Subscribe to Dr. Greger's free nutrition newsletter at http://www.nutritionfacts.org/subscribe and get a free excerpt from his latest NYT Bestseller HOW NOT TO ...
All three groups who were given lesinurad showed substantially lower uric acid levels at the end of the month. The percentage of patients who achieved the target for uric acid levels after treatment was 28% in the placebo group, 71% in the 200 mg party, 76% in the 400 mg group, and 87% in the 600 mg group.
More lately, shares of BioCryst Pharmaceuticals rose 12% upon the release of the results of its phase 2b randomized, double-blind, study from the investigational gout drug BCX4208. BCX4208 is a novel enzyme inhibitor that acts upstream of xanthine oxidase in the purine metabolism pathway to reduce serum uric acid (sUA).
Can Stress Aggravate Gout? Stress may be causing you to shake your head in frustration. That six-letter word is taking the blame for everything from headaches to heartaches nowadays. Since the day of the caveman, the world is full of enough uncertainty to make stress...
Its mechanism of action complements xanthine oxidase inhibitors such as allopurinol and also febuxostat in reducing uric acid production, and BCX4208 is intended as an add-on therapy for those gouty osteoarthritis patients who will not respond well in order to current gout medication.
Like Lesinurad, BCX4208 was studied in gouty arthritis patients who had experienced high blood urate levels for at least 6 months, despite taking the gout drug allopurinol. The 279 study participants were randomly assigned to take BCX4208 at doses of possibly 5 mg, 10 mg, 20 mg, or 40 mg once daily for 12 weeks. One group of sufferers was given a placebo. Almost all participants were also given allopurinal 300 mg once-daily.
- All but one of the doses showed that BCX4208 was superior to the placebo when taken with allopurinol.
- The BCX4208 doses examined in the study showed response rates ranging from 33% in order to 49%, compared to 18% for those taking the placebo.
At this point, Lesinurad appears the more promising of the two gout medications, and the most likely to hit the market first. It outperformed BCX4208 in early clinical trials, and is farther ahead in the development and approval process. But individual responses to drugs vary, and gout patients will benefit from having two new approaches to reducing the symptoms of this painful condition.
Alex Ray Advocates Regarding Affordable Access to Healthcare and Medication
She recommends Big Mountain Drugs as a reliable on the internet Canadian pharmacy from which to buy allopurinol and colchicine for gout. For more information about gout and gout medication, visit the on the internet resource www.colchicine.ca.